Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
June 18 2021 - 8:00AM
Business Wire
As an independent director, Dr. Chung brings
deep expertise in healthcare investment and corporate
development
Aditx Therapeutics, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech
innovation company with a mission to improve the health of the
immune system, announced today that Dr. Lauren Chung will join the
Aditxt board of directors as an independent director.
“As a new independent director of Aditxt’s board, Dr. Chung
brings deep insights spanning global scientific, investment and
business communities, and these experiences strongly complement our
future growth goals,” said Amro Albanna, co-founder and CEO of
Aditxt. “We look forward to working with Dr. Chung as we establish
our portfolio of first-in-human clinical studies, launch new
high-growth verticals for our AditxtScoreTM immune intelligence
platform, and explore partnership strategies across the globe.”
Dr. Chung has over 20 years of healthcare investment management,
investment banking, and advisory experience, and is currently a
venture partner at Yozma Group Korea. She is the founder and CEO of
MINLEIGH LLC, which is focused on identifying, evaluating, and
partnering with companies for investments and strategic,
operational, and commercial opportunities.
Prior to her current roles, Dr. Chung was a managing director in
Healthcare Research at WestPark Capital. Previously, she was a
co-founder of Tokum Capital Management, a global healthcare fund,
which merged with Perella Weinberg Partners. Prior to that, Dr.
Chung managed healthcare investment portfolios at institutional
investment firms. Earlier in her career, Dr. Chung was a research
scientist doing cutting-edge work in neurodegenerative and genetic
disorders at Massachusetts General Hospital/Harvard Medical School
and Boston Children’s Hospital.
Dr. Chung has published in many leading peer-reviewed scientific
journals, and as a current and former director of public and
private companies, she brings a valuable perspective for the
company’s strategy and operations, as well as extensive scientific
insights.
About Aditxt:
Aditxt is developing technologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. Aditxt’s immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. Aditxt’s immune reprogramming technology is
currently at the pre-clinical stage and is designed to retrain the
immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and
allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements:
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s intellectual property position; the Company’s ability
to develop commercial functions; expectations regarding product
launch and revenue; the Company’s results of operations, cash
needs, spending, financial condition, liquidity, prospects, growth
and strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section
titled “Risk Factors” in the Company’s most recent Annual Report on
Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210618005027/en/
Media and Investor Relations Contact: Sunny Uberoi Chief
Communications Officer Aditxt ir@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024